SomnoMed Limited (ASX:SOM)
Australia · Delayed Price · Currency is AUD | Market Cap | 125.97M +11.0% |
| Revenue (ttm) | 118.50M +18.2% |
| Net Income | -2.56M |
| EPS | -0.01 |
| Shares Out | 219.08M |
| PE Ratio | n/a |
| Forward PE | 29.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,524 |
| Average Volume | 61,207 |
| Open | 0.6000 |
| Previous Close | 0.6200 |
| Day's Range | 0.5750 - 0.6000 |
| 52-Week Range | 0.4000 - 0.9450 |
| Beta | 0.94 |
| RSI | 47.66 |
| Earnings Date | Feb 26, 2026 |
About SomnoMed
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te... [Read more]
Financial Performance
In fiscal year 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.
Financial StatementsNews
SomnoMed Ltd (SOMNF) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic ...
SomnoMed Ltd (SOMNF) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic Investments
Half Year 2026 Somnomed Ltd Earnings Call Transcript
Half Year 2026 Somnomed Ltd Earnings Call Transcript
SomnoMed Earnings Call Transcript: H1 2026
Revenue grew 13% to AUD 60.7 million with EBITDA up 35% and stable gross margins. Europe and North America drove growth, while APAC softened. Guidance for FY 2026 is reaffirmed, with continued investment in manufacturing, R&D, and innovation, notably RestAssure.
SomnoMed Earnings Call Transcript: H2 2025
FY2025 delivered 22% revenue growth to $111.5 million, a dramatic EBITDA turnaround, and positive cash flow, driven by operational improvements and strong regional performance. FDA clearance for Rest Assure and expanded manufacturing set the stage for continued growth in FY2026.
SomnoMed Earnings Call Transcript: H1 2025
Revenue grew 19% to AUD 53.7 million in H1 FY2025, with EBITDA improving to AUD 5.8 million and all regions achieving double-digit growth. Upgraded FY2025 guidance projects AUD 105 million revenue and AUD 7–9 million EBITDA, supported by operational efficiencies and a strengthened balance sheet.
SomnoMed Earnings Call Transcript: H2 2024
Revenue grew 9.6% to AUD 91.7 million in FY 2024, with EBITDA at AUD 0.6 million amid capacity constraints and margin pressure. FY 2025 guidance targets over 9% revenue growth and EBITDA above AUD 5 million, supported by manufacturing investments and strong early trading.